NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

Cancer

Volumn 118, Issue 18, 2012, Pages 4564-4570

  Pollack, Seth M ^a,b   Jungbluth, Achim A ^c   Hoch, Benjamin L ^b   Farrar, Erik A ^a   Bleakley, Marie ^a,d   Schneider, David J ^b   Loggers, Elizabeth T ^a,b,e   Rodler, Eve ^b   Eary, Janet F ^d   Conrad III, Ernest U ^b   Jones, Robin L ^a,b   Yee, Cassian ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e GROUP HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

cancer testis antigens; immunotherapy; myxoid; NY ESO 1; sarcoma

Indexed keywords

CD8 ANTIGEN; CHROMIUM; NY ESO 1 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPOSARCOMA; MYXOSARCOMA; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SOFT TISSUE SARCOMA; SOLID TUMOR; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LIPOSARCOMA, MYXOID; MEMBRANE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84865961414     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27446     Document Type: Article

References (45)

1. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A. 2004; 101: 10697-10702.
2. Nicholaou T, Ebert LM, Davis ID, et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res. 2009; 15: 2166-2173.
3. Jager E, Karbach J, Gnjatic S, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A. 2006; 103: 14453-14458.
4. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008; 358: 2698-2703.
5. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29: 917-924.
6. Chen YT, Scanlan J, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997; 94: 1914-1918.
7. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254: 1643-1647.
8. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998; 187: 265-270.
9. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995; 13: 1537-1545.
10. Jones RL, Fisher C, Al-Muderis O, Judson IR,. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005; 41: 2853-2860.
11. Conyers R, Young SS, Thomas M,. Liposarcoma: molecular genetics and therapeutics [serial online]. Sarcoma 2011: 483154, 2011.
12. Aman P, Ron D, Mandahl N, et al. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer. 1992; 5: 278-285.
13. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007; 8: 595-602.
14. Jungbluth AA, Antonescu CR, Busam KJ, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer. 2001; 94: 252-256.
15. Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 2001; 92: 856-860.
16. Vaughan HA, Svobodova S, Macgregor D, et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res. 2004; 10: 8396-8404.
17. Pattyn F, speleman F, De Paepe A, Vandesompele J,. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res. 2003; 31: 122-123.
18. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N,. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996; 196: 121-135.
19. Li Y, Yee C,. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood. 2008; 111: 229-235.
20. Riddell SR, Greenberg PD,. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990; 128: 189-201.
21. Crozat A, Aman P, Mandahl N, Ron D,. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993; 363: 640-644.
22. Bleakley M, Otterud BE, Richardt JL, et al. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood. 2010; 115: 4923-4933.
23. Segal NH, Blachere NE, Guevara-Patino JA, et al. Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics [serial online]. Cancer Immun. 2005; 5: 2.
24. Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP,. Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors [serial online]. J Transl Med. 2008; 6: 23.
25. Skubitz KM, Cheng EY, Clohisy DR, Thompson RC, Skubitz AP,. Differential gene expression in liposarcoma, lipoma, and adipose tissue. Cancer Invest. 2005; 23: 105-118.
26. Segal NH, Pavlidis P, Antonescu CR, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol. 2003; 163: 691-700.
27. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007; 67: 6626-6636.
28. Ayyoub M, Taub RN, Keohan ML, et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma [serial online]. Cancer Immun. 2004; 4: 7.
29. Andersson MK, Stahlberg A, Arvidsson Y, et al. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response [serial online]. BMC Cell Biol. 9: 37, 2008.
30. Hoell JI, Larsson E, Runge S, et al. RNA targets of wild-type and mutant FET family proteins. Nat Struct Mol Biol. 2011; 18: 1428-1431.
31. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992; 359: 162-165.
32. Brody RI, Ueda T, Hamelin A, et al. Molecular analysis of the fusion of EWS to an orphan nuclear receptor gene in extraskeletal myxoid chondrosarcoma. Am J Pathol. 1997; 150: 1049-1058.
33. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa C, et al. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer. 2007; 120: 67-74.
34. Rodriguez R, Rubio R, Gutierrez-Aranda I, et al. FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells. Stem Cells. 2011; 29: 179-192.
35. Riggi N, Cironi L, Provero P, et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res. 2006; 66: 7016-7023.
36. Panagopoulos I, Mandahl N, Ron D, et al. Characterization of the CHOP breakpoints and fusion transcripts in myxoid liposarcomas with the 12;16 translocation. Cancer Res. 1994; 54: 6500-6503.
37. Panagopoulos I, Lassen C, Isaksson M, Mitleman F, Mandahl N, Aman P,. Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia. Oncogene. 1997; 15: 1357-1362.
38. Nagai M, Tanaka S, Tsuda M, et al. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci U S A. 2001; 98: 3843-3848.
39. Cironi L, Provero P, Riggi N, et al. Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1 [serial online]. PLoS One. 2009; 4: e7904.
40. Antonescu CR, Busam KJ, Iverson K, et al. MAGE antigen expression in monophasic and biphasic synovial sarcoma. Hum Pathol. 2002; 33: 225-229.
41. Lee SY, Obata Y, Yoshida M, et al. Immunomic analysis of human sarcoma. Proc Natl Acad Sci U S A. 2003; 100: 2651-2656.
42. Zou C, Shen J, Tang Q, et al. Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis [published online ahead of print August 26, 2011]. Cancer. 2011.
43. Cuffel C, Rivals JP, Zaugg Y, et al. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer. 2011; 128: 2625-2634.
44. Lendvai N, Gnjatic S, Ritter E, et al. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients [serial online]. Cancer Immun. 2010; 10: 4.
45. Frapolli R, Tamborini E, Virdis E, et al. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors. Clin Cancer Res. 2010; 16: 4958-4967.